Cytogen, Inc.
Financials
Valuation Metrics
Cytogen, Inc.'s Market Cap is ₩716B. At end of 2025 it was ₩2079B. Ranked #1522 of 2,421 in KR market (top 63%), #893 of 1,640 on KOSDAQ (top 54%), #165 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 71.59B KRW | KR#1,522/2,421 Sec#165/231 |
| Revenue | 27.38B KRW | KR#2,059/2,421 Sec#143/231 |
| Net Income | -10.55B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 54.75B KRW | KR#2,162/2,421 Sec#191/231 |
| Net Assets | 33.75B KRW | KR#2,139/2,421 Sec#188/231 |
| Employees | 50 | KR#2,050/2,421 Sec#189/231 |
| Value | ||
| P/B | 2.12x | KR#1,969/2,421 Sec#148/231 |
| P/S | 2.61x | KR#1,932/2,421 Sec#114/231 |
| FCF Yield | -12.47% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -31.25% | KR#2,194/2,421 Sec#178/231 |
| ROA | -19.26% | KR#2,236/2,421 Sec#174/231 |
| Op. Margin | -23.94% | KR#2,149/2,421 Sec#150/231 |
| Revenue Growth | 31.63% | KR#368/2,421 Sec#36/231 |
| Financial Health | ||
| Debt Ratio | 62.24% | KR#1,122/2,421 Sec#133/231 |
| Total Debt | 13.12B KRW | KR#1,537/2,421 Sec#133/231 |
| FCF | -8.92B KRW | KR#1,669/2,421 Sec#142/231 |
| Cash | 14.89B KRW | KR#1,434/2,421 Sec#113/231 |
| Current Ratio | 7.49x | KR#161/2,421 Sec#36/231 |
| Performance | ||
| 1Y Return | 24.55% | KR#392/2,421 Sec#26/231 |
| 1M Return | -8.30% | KR#2,019/2,421 Sec#168/231 |
| From 52W High | -72.37% | KR#2,243/2,421 Sec#194/231 |
| 1Y MDD | -70.01% | KR#1,987/2,421 Sec#171/231 |
| Trading | ||
| Volume | 38,795 shares | KR#1,252/2,421 Sec#123/231 |
| Trading Value | 118.0M KRW | KR#1,484/2,421 Sec#150/231 |
| Foreign Own. | 2.04% | KR#1,612/2,421 Sec#156/231 |
| Per Share | ||
| EPS | -456 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,459 KRW | KR#2,206/2,421 Sec#192/231 |
Company Info
The company, established in 2013, is a precision medicine specialist firm with CTC-based liquid biopsy platform technology. In 2024, it diversified its business by acquiring Genome Care, a prenatal and postnatal diagnostics specialist, and now offers anti-cancer new drug development support to pharmaceutical companies, medical device distribution, and health functional food sales. Accelerating global market expansion with US and Japan subsidiaries, the company strengthens its position in the precision medicine market through technology commercialization in cooperation with major hospitals and pharmaceutical companies. Cytogen was established in 2010 and is headquartered in Songpa-gu, Seoul.